1. Introduction {#sec1}
===============

Early afterdepolarizations (EADs) are triggered before the completion of repolarization \[[@B1]\] and associated with polymorphic ventricular tachyarrhythmia for long QT syndrome patients \[[@B2]\]. Prolongation of action potential duration (APD) and recovery of L-type Ca^2+^ current have been reported as two important factors for the occurrence of EADs \[[@B3]\]. It is also known that the increase of inward currents (e.g., *I* ~CaL~ and late sodium current, *I* ~NaL~) or the decrease of outward currents (e.g., rapid delayed rectifier K^+^ current, *I* ~Kr~ and slow delayed rectifier K^+^ current, *I* ~Ks~) at plateau membrane voltage could increase the probability of EADs events. Therefore, any factors that could change the intensity or time sequence of these currents may lead to the occurrence of EADs \[[@B4]--[@B8]\].

Ca^2+^/calmodulin-dependent protein kinase II (CaMKII) is a key kinase in tuning cardiac excitation-contraction coupling. Its substrates include ion channels, transporters, and accessory proteins \[[@B9]\]. It has been reported that CaMKII phosphorylates *I* ~CaL~, leading to increased amplitude and APD prolongation and facilitating the occurrence of EADs \[[@B10], [@B11]\]. CaMKII can also alter *I* ~NaL~, transient outward K current (*I* ~to~), SR Ca^2+^-ATPase (SERCA) \[[@B12]\], and ryanodine receptor (RyR) channels \[[@B10]\]. It would therefore be useful to understand and quantify these regulatory roles. However, it is very difficult for the laboratory experiments to achieve this. Computer modelling approaches provide alternative ways, allowing us to distinguish the most effective phosphorylation target of arrhythmogenesis, which would ultimately provide useful tool in searching for antiarrhythmia therapy.

It has been known that *β*-adrenergic signaling pathway regulates Ca^2+^ cycling partly via phosphorylation of *I* ~CaL~ and phospholamban (PLB) \[[@B13]\]. *I* ~CaL~ elevates intracellular Ca^2+^ (\[Ca\]~i~) and increases spontaneous Ca^2+^ release via the SERCA inhibition by PLB. The broken balance of Ca^2+^ cycling may contribute to the occurrence of EADs \[[@B14]--[@B16]\]. Volders et al. investigated the ionic mechanisms of *β*-adrenergic on the occurrence of EADs in canine ventricular myocyte and concluded that cellular Ca^2+^ overload and spontaneous SR Ca^2+^ release played important roles in EADs \[[@B17]\]. On the contrary, other studies reported that *β*-adrenergic agonists activate protein kinase A (PKA), which phosphorylates *I* ~CaL~, RyR, PLB, SERCA, and *I* ~Ks~, resulting in delayed afterdepolarization (DADs) \[[@B18]\]. These numerous targets and different temporal characteristics of phosphorylation effects complicate the mechanism analysis of *β*-adrenergic agonists in relation to EADs. Recently, different computational models have been used to investigate these complex interactions. Xie et al. developed a biophysically detailed rabbit model and found that the faster time course of *I* ~CaL~ versus *I* ~Ks~ increased ISO-induced transient EADs \[[@B19]\] and emphasized the importance of understanding the nonsteady state of kinetics in meditating *β*-adrenergic-induced EADs and arrhythmia. However, other targets including *I* ~NaL~ have not been investigated thoroughly in their model. It is noted that, although the computational studies of EAD mechanisms have been widely taken, the majority of these published modelling studies have been developed based on nonhuman myocyte. Furthermore, to the best of our knowledge, there is no modelling study considering the combined effect of CaMKII overexpression and *β*-adrenergic agonists on EADs.

This study aimed to develop a modified computational model of human ventricular myocyte that integrates CaMKII and *β*-adrenergic signaling networks into a modified ORd\'s dynamic model \[[@B20]\], with which the combined role of CaMKII and *β*-adrenergic signaling pathway on the occurrence of EADs would be investigated.

2. Methods {#sec2}
==========

2.1. Integration of CaMKII {#sec2.1}
--------------------------

Since there is a lack of experimental measurements of human ventricle CaMKII pathway, O\'Hara et al. used the Hund-Decker-Rudy\'s dog model to describe CaMKII kinetics \[[@B21], [@B22]\]. Our model was developed from the O\'Hara-Rudy dynamic model (ORd model) to integrate CaMKII pathway \[[@B20]\]. The following equations describe the CaMKII kinetic of human ventricle:$$\begin{matrix}
{\text{CaMK}_{\text{bound}} = \text{CaMK}_{\text{0}} \cdot \frac{1 - \text{CaMK}_{\text{trap}}}{1 + {\text{K}_{m\text{CaM}}/\left\lbrack {\text{C}\text{a}^{\text{2+}}} \right\rbrack_{\text{ss}}}},} \\
 \\
{\text{CaMK}_{active} = \text{CaMK}_{bound} + \text{CaMK}_{trap},} \\
 \\
{\frac{{d\text{CaMK}}_{\text{trap}}}{dt} = \alpha_{\text{CaMK}} \cdot \text{CaMK}_{\text{bound}} \cdot \left( {\text{CaMK}_{\text{bound}} + \text{CaMK}_{\text{trap}}} \right) - \beta_{\text{CaMK}} \cdot \text{CaMK}_{\text{trap}},} \\
 \\
{\mspace{17320mu}\alpha_{\text{CaMK}} = 0.05\,\text{m}\text{s}^{- 1},\,\,\beta_{\text{CaMK}} = 0.00068\,\,\text{m}\text{s}^{- 1},\,\,\text{CaMK}_{0} = 0.05,\,\, K_{m\text{CaM}} = 0.0015\,\text{mM}.} \\
\end{matrix}$$

The fraction of active CaMKII binding sites at equilibrium state (CaMK~0~) was set to 0.05 at the control state. CaMK~0~ of 0.12 was used to simulate CaMKII overexpression according to the study from Kohlhaas et al. \[[@B23]\].

2.2. Integration of *β*-Adrenergic Signaling Networks {#sec2.2}
-----------------------------------------------------

The detailed description of *β*-adrenergic signaling networks could be found from the published study by Soltis and Saucerman \[[@B24]\]. PKA has been reported to phosphorylate *I* ~CaL~, PLB, troponin *I*, RyR, myosin binding protein-C, protein phosphates Inhibitor-*I* \[[@B25]\], and *I* ~Ks~ \[[@B24]\]. *I* ~CaL~, PLB, and *I* ~Ks~ were the three key factors in this study to model the inotropic effect of *β*-adrenergic related to potential EADs occurrence. Although the PKA phosphorylation of Na^+^/K^+^ ATPase current (*I* ~NaK~) has been previously described in the computational models \[[@B19], [@B26]\], its effect was not included in this study partially because there is a lack of direct measurements of *I* ~NaK~ for the normal human ventricle \[[@B20]\]. The phosphorylation by PKA to the three targets (*I* ~CaL~, PLB, and *I* ~Ks~) is described as follows:$$\begin{matrix}
{f_{avail} = 0.017 \cdot \frac{LC{C_{b}}_{PKA_{P}}}{fracLCC_{bp0}} + 0.983,} \\
\end{matrix}$$ $$\begin{matrix}
{dss = \frac{1}{1.0 + {\exp\left( {{- \left( {V + vshift} \right)}/4.230} \right)}},} \\
\end{matrix}$$ $$\begin{matrix}
{I_{CaL} = \left( {\overset{¯}{I_{CaL}} \cdot d \cdot \left( { 1 - \phi_{I_{CaL,CaMK}}} \right)\mspace{1800mu} \cdot \left( { f \cdot \left( { 1 - \textit{n}} \right) + f_{Ca} \cdot n \cdot j_{Ca}} \right) + \overset{¯}{I_{CaL,CaMK}} \cdot d\mspace{1800mu} \cdot \phi_{I_{CaL,CaMK}} \cdot \left( { f_{CaMK} \cdot \left( { 1 - n} \right) + f_{Ca,CaMK} \cdot n \cdot j_{Ca}} \right)} \right)} \\
{\mspace{1800mu} \cdot f_{\text{avail}},} \\
\end{matrix}$$ $$\begin{matrix}
{\Phi_{I_{CaL,CaMK}} = \frac{1}{1 + {{Km,CaMK}/{CaMK_{active}}}},} \\
\end{matrix}$$ $$\begin{matrix}
{td = 1.2 \cdot \left( { 0.6\mspace{1800mu} + \frac{1}{{\exp\left( {- 0.05 \cdot \left( {V + 6.0} \right)} \right)} + {\exp\left( {0.09 \cdot \left( {V + 14.0} \right)} \right)}}} \right).} \\
\end{matrix}$$

Equation ([2](#EEq4){ref-type="disp-formula"}) shows the coefficient that represents the effect of PKA on *I* ~CaL~ phosphorylation. In ([3](#EEq5){ref-type="disp-formula"}), the value of "*v*shift" was increased from 3.94 (no ISO application) to 10.0 (for saturated ISO application), which means that the steady state activation curve of *I* ~CaL~ was moved left by 6.06 mV. The permeability of ion Ca^2+^ was increased by 10% with saturated ISO application. Equation ([4](#EEq6){ref-type="disp-formula"}) describes the augmentation of *I* ~CaL~ amplitude by multiplying "*f* ~avail~" with the value without PKA phosphorylation, and this represents how PKA regulates *I* ~CaL~. In ([6](#EEq8){ref-type="disp-formula"}), the time constant of activation gate (*td*) was extended by 20% with saturated ISO application $$\begin{matrix}
{\text{frac}I_{\text{Ksavail}} = 0.49 \cdot \frac{{I_{\text{Ks}}}_{\text{PKA}_{\textit{P}}}}{{\text{frac}I_{\text{Ks}}}_{\textit{p}0}} + 0.51,} \\
 \\
\end{matrix}$$ $$\begin{matrix}
{\text{GKs} = \text{frac}I_{\text{Ksavail}} \cdot \text{GKs},} \\
 \\
\end{matrix}$$ $$\begin{matrix}
{Xs05 = 11.60 \cdot fracI_{Ksavail},} \\
 \\
\end{matrix}$$ $$\begin{matrix}
{X_{S1,\infty} = \frac{1}{1 + {\exp\left( {{- \left( {V + Xs05} \right)}/8.932} \right)}}.} \\
 \\
\end{matrix}$$

Equation ([7](#EEq9){ref-type="disp-formula"}) describes the factor of phosphorylation to *I* ~Ks~ by PKA, which was used to alter maximum conductance of *I* ~Ks~ (GKs) in ([8](#EEq10){ref-type="disp-formula"}). Meanwhile, *I* ~Ks~ state steady activation curve was adjusted by time dependent gate value through the factor "frac*I* ~Ksavail~" in ([9](#EEq11){ref-type="disp-formula"}) and ([10](#EEq12){ref-type="disp-formula"}).

2.3. Combination of CaMKII and *β*-Adrenergic Signaling Networks {#sec2.3}
----------------------------------------------------------------

$$\begin{matrix}
{fPKA_{PLB} = \left( {\frac{PLB\_ PKA_{n}}{fracPKA_{PLB_{0}}}} \right) \cdot \frac{1}{4} + \frac{3}{4},} \\
\end{matrix}$$ $$\begin{matrix}
{fJupp = \frac{1.0}{\left( {1.0 + K_{m,CaMK} \cdot \left( {{fPKA_{PLB}}/{CaMK_{active}}} \right)} \right)},} \\
\end{matrix}$$ $$\begin{matrix}
{Jup = \left( { 1.0 - fJupp} \right) \cdot Jupnp + fJupp \cdot Jupp - Jleak.} \\
\end{matrix}$$

CaMK~active~ that is affected by CaMK~0~ as shown in ([1](#EEq1){ref-type="disp-formula"}) would influence *I* ~CaL~ in ([4](#EEq6){ref-type="disp-formula"}) via the fraction of *I* ~CaL~ channels phosphorylated by CaMKII (Φ~*I*~CaL,CaMK~~). The fraction of SERCAs phosphorylated by CaMKII in ([12](#EEq14){ref-type="disp-formula"}) was affected by "fPKA~PLB~" and "CaMK~active~", representing the effects of PKA and CaMKII on SERCAs, respectively. As shown in ([13](#EEq15){ref-type="disp-formula"}), SERCAs were separated into nonphosphorylated populations and CaMKII phosphorylated populations. Therefore, the total Ca^2+^ uptake via SERCAs was adjusted by these two networks simultaneously.

2.4. Simulation Strategy {#sec2.4}
------------------------

In order to determine the potential targets in CaMKII-induced EADs, CaMKII was solely overexpressed by assigning the CaMK~0~of 0.12 to specific targets (including *I* ~NaL~, *I* ~CaL~, *I* ~CaK~, *I* ~NaCa~, and *I* ~to~), respectively, while *β*-adrenergic signaling was maintained inactive. Next, CaMKII overexpression was applied with ISO administration. 1 *μ*M ISO was applied in this study to simulate its effect on myocyte action potential and ion currents.

The cycle length of 2000 ms was used in this study since it was closer to normal human beat rhythm than the length of 4000 ms used in the experiments from Guo et al. \[[@B27]\]. In Guo et al.\'s work, EADs appeared with *I* ~Kr~ blockage of about 85% \[[@B27]\], which was used for comparison in this study. 500 cycles were performed when the simulation reached steady state. In each individual cycle length, the upper bound of solver step size was set 2 ms.

3. Results {#sec3}
==========

3.1. Effect of CaMKII Overexpression on Ion Currents {#sec3.1}
----------------------------------------------------

### 3.1.1. Late Sodium Current (*I* ~NaL~) {#sec3.1.1}

As shown in [Table 1](#tab1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}, with the overexpressed CaMK~0~ value to *I* ~NaL~ of 0.12 and the normal CaMK~0~ value of 0.05 to other targets, the alternated EADs occur from our simulation with the cycle length (CL) of 2000 ms and *I* ~Kr~ blockage of 85%.

As shown in [Figure 1](#fig1){ref-type="fig"}, I~NaL~ amplitudes alternated with overexpressed CaMK~0~. In beats with EADs, *I* ~NaL~ amplitude was about 24% smaller (0.19 *μ*A/*μ*F versus 0.25 *μ*A/*μ*F) than these with normal CaMK~0~ value to *I* ~NaL~ and in beats without EADs, *I* ~NaL~ amplitude was also reduced by 32% (0.17 *μ*A/*μ*F versus 0.25 *μ*A/*μ*F). In [Figure 1(d)](#fig1){ref-type="fig"}, when EADs occurred, *I* ~NaL~ deactivated, which was about 168% of normal beats (1297 ms versus 773 ms) and about 170% of the control situation in [Figure 1(b)](#fig1){ref-type="fig"} (1297 ms versus 761 ms), indicating that overexpressed CaMKII phosphorylation level of *I* ~NaL~ reduces its amplitude and prolongs *I* ~NaL~ deactivation process. Furthermore, the results also indicate that the delayed deactivation of *I* ~NaL~, rather than its amplitude variation, contributes to the formation of EADs.

### 3.1.2. L-Type Calcium Current (*I* ~CaL~) {#sec3.1.2}

Similarly, as shown in [Table 1](#tab1){ref-type="table"}, with the overexpressed CaMK~0~ to *I* ~CaL~ of 0.12 and the normal CaMK~0~ value of 0.05 to other targets, no EADs occur at CL of 2000 ms and *I* ~Kr~ blockage of 85%, suggesting that the probability of EADs might have little relation with amplitude of *I* ~CaL~. With the enhanced CaMK~0~ value to *I* ~CaL~, the amplitudes of *I* ~CaL~ only increased by 4.2% (1.74 *μ*A/*μ*F versus 1.67 *μ*A/*μ*F).

### 3.1.3. K^+^ Current through the L-Type Ca^2+^ Channel (*I* ~CaK~), Na^+^ Current through the L-Type Ca^2+^ Channel (*I* ~CaNa~), and Transient Outward K^+^ Current (*I* ~to~) {#sec3.1.3}

As above, CL was set to 2000 ms and *I* ~Kr~ was blocked by 85%. As shown in [Table 1](#tab1){ref-type="table"}, with enhanced CaMKII phosphorylation level (CaMK~0~ = 0.12) to different targets, *I* ~CaK~ increased only by 6.5% (0.66 *μ*A/*μ*F versus 0.62 *μ*A/*μ*F), *I* ~CaNa~ by 8.1% (0.40 *μ*A/*μ*F versus 0.37 *μ*A/*μ*F), and *I* ~to~ by 3.2% (0.98 *μ*A/*μ*F versus 0.95 *μ*A/*μ*F). No EADs occurred under all these conditions.

3.2. Combined Effect of CaMKII Overexpression and *β*-Adrenergic Agonist {#sec3.2}
------------------------------------------------------------------------

### 3.2.1. Normal CaMKII and 1 *μ*M ISO {#sec3.2.1}

The action potentials with different *I* ~Kr~ blockage level are shown in [Figure 2](#fig2){ref-type="fig"}. A fixed CL =2000 ms was used and CaMKII phosphorylation level to all targets was kept control (CaMK~0~ = 0.05). In [Figure 2(a)](#fig2){ref-type="fig"}, with *I* ~Kr~ blocked by 85%, stable EADs occurred with the application of ISO, indicating that *β*-adrenergic agonist facilitates EADs. The *I* ~Kr~ blockage level decreased gradually from 85%, and, when it was decreased to 77%, as shown in [Figure 2(b)](#fig2){ref-type="fig"}, these EADs disappeared, indicating that 77% was the threshold value for EADs disappearance in this setting. Therefore, 77% was used in following simulation to compare with previously published level of 85% \[[@B20]\]. These results are listed from row 2 to row 3 in [Table 2](#tab2){ref-type="table"}.

### 3.2.2. Enhanced CaMKII to *I* ~NaL~ and 1 *μ*M ISO {#sec3.2.2}

As shown in [Figure 3](#fig3){ref-type="fig"}, with enhanced CaMKII to *I* ~NaL~ and 1 *μ*M ISO, when *I* ~Kr~ was blocked by 85%, EADs were induced. The EADs were still observed when *I* ~Kr~ was blocked by 77%, suggesting that *I* ~NaL~ phosphorylation by CaMKII and ISO application together increased the probability of EADs. These results are listed from row 4 to row 5 in [Table 2](#tab2){ref-type="table"}.

### 3.2.3. Enhanced CaMKII to *I* ~CaL~ and 1 *μ*M ISO {#sec3.2.3}

As shown in [Figure 4](#fig4){ref-type="fig"}, with enhanced CaMKII to *I* ~CaL~ and 1 *μ*M ISO, when *I* ~Kr~ was blocked by 85%, EADs were induced, but when *I* ~Kr~ blockage was reduced to 77%, EADs disappeared. These results are listed from row 6 to row 7 in [Table 2](#tab2){ref-type="table"}.

4. Discussion {#sec4}
=============

This study developed a modified computational model of human ventricular myocardium cell based on the ORd human model with the integration of regulation mechanism by CaMKII and PKA \[[@B20]\], with which their effects on EADs have been investigated.

EADs often occur during bradycardia under the condition of reduced repolarization reserve. O\'Hara\'s group successfully elicited EADs with cycle length reduced to 4000 ms and *I* ~Kr~ blocked by 85% \[[@B20]\]. In our simulation, with the cycle length halved (2000 ms) and *I* ~Kr~ blocked by 85%, alternated EADs occurred with the sole effect of CaMKII overexpression to *I* ~NaL~, suggesting that ventricular myocardial cell with CaMKII overexpression is more susceptible to EADs in normal HR range (CL = 2000 ms). Additionally, previous work has shown that *I* ~CaL~ plays an important role in the occurrence of EADs \[[@B6]\]. Our simulation showed that CaMKII overexpression slightly increased *I* ~CaL~ amplitude, but this effect alone did not induce EADs, and CaMKII did not alter the overlap region of *I* ~CaL~ steady state activation and reactivation curves. Zaza et al. reported that \[[@B29]\], when repolarization is suitably slow, channel reactivation within the overlap region may break the current balance and support the possibility of autoregenerative depolarization. Other inward currents such as Na^+^-Ca^2+^ exchange current (*I* ~NaCa~) may play certain roles in triggering EADs if amplitude is augmented and falls into the overlap region. Our simulation results suggest that CaMKII enhances these currents but does not induce EADs via this effect individually. Therefore, when CaMKII is overexpressed, the susceptibility to EADs is mainly originated from *I* ~NaL~ variation.

Our study also demonstrated the behavior of ventricular myocardial cell with the integration of CaMKII overexpression and ISO application. With the ISO application, cyclic AMP (cAMP) is formed through *β*-adrenergic mediated activation of adenylyl cyclase, which activates PKA, a well-described mediator with targets that promote myocardial performance. In the case where PKA took effect independently, EADs occurred with shorter cycle length (2000 ms versus 4000 ms), indicating that the precondition of EADs is relaxed. Our results were different from that from Xie et al.\'s study, where the APD shortening after ISO application was observed without EADs in steady state \[[@B19]\]. Xie et al.\'s results could be caused by the simulation of transient *I* ~CaL~ recovery and the prevented spontaneous SR Ca^2+^ release, limiting the *I* ~NaCa~ in forward mode. Therefore, when the cells step into steady state with small inward *I* ~NaCa~, the shortening of APD could be reasonable. In our work, SR Ca^2+^ release was enhanced by *I* ~CaL~ amplification. With the integration with *I* ~Kr~ blockage, *I* ~NaCa~ was more likely to work as inward current, contributing to the prolongation of APD and occurrence of EADs. Additionally, the shortening of APD was also obtained without *I* ~Kr~ blockage when *β*-adrenergic pathway was activated. Simulation results showed that when cycle length was chosen at 500 ms, 1000 ms, 1500 ms, 2000 ms, and 4000 ms, the corresponding APD90 shortening was 31.6 ms (233.0 versus 201.4 ms), 30.5 ms (268.6 versus 238.1 ms), 22.3 ms (282.6 versus 260.3 ms), 17.3 ms (289.1 versus 271.8 ms), and 18.6 ms (305.6 versus 287.0 ms). These results were consistent with the experiment measurements from Volders et al. \[[@B30]\]. In the case that CaMKII overexpression acted on *I* ~NaL~ alone with ISO application, EADs occur at CL = 2000 ms and *I* ~Kr~ blockage by 77%, suggesting that the combination of PKA and CaMKII overexpression on *I* ~NaL~ relaxes the precondition further (*I* ~Kr~ blockage 77% versus 85%) and increases the probability of EADs. With the CaMKII overexpressed on *I* ~CaL~ alone, PKA induced EADs occurrence with 85%  *I* ~Kr~ blockage, not 77%  *I* ~Kr~ blockage, suggesting that, with the ISO application, *I* ~NaL~ phosphorylation by CaMKII has more effect on EADs than *I* ~CaL~. The steady state of CaMK~active~ was simulated with and without ISO application when CL = 2000 ms, and their corresponding maximum values were 0.0469 and 0.0421, respectively. This suggests that CaMKII activation increased with the application of ISO.

Our simulation results have shown that our proposed model is useful for exploring the interaction of *β*-adrenergic receptor signaling and CaMKII in formation of EADs; some potential limitations need to be addressed. Firstly, the role of CaMKII on RyR function has not been considered. There is growing evidence about its role in modulating RyR function. Increasing Ca^2+^ leak via RyR would limit SR Ca^2+^ load and disturb Ca^2+^ cycling. This should be incorporated into an improved model in a future study. Secondly, CaMKII overexpression may downregulate inward rectifier potassium current (*I* ~K1~) and increase baseline *I* ~K1~ amplitude \[[@B31]\]. We did not include any CaMKII effect on *I* ~K1~ in our model. Thirdly, our model only describes the short-term effect of CaMKII on different current targets. It has been suggested that short-term and chronic effects of CaMKII are different \[[@B31]--[@B34]\]. Short-term (milliseconds to hours) CaMKII overexpression may slow *I* ~to~ inactivation and accelerate recovery, but chronic overexpression may downregulate *I* ~to,fast~ and upregulate *I* ~to,slow~ \[[@B35]\]. Therefore, there is a scope to improve our model by taking chronic effects of CaMKII into consideration in future. Fourthly, there is a lack of an accurate measurement about how ISO regulates *I* ~NaK~ with dynamic calcium change during the beat cycle, although it has been published by Gao et al. \[[@B36]\] that ISO regulated I~NaK~ increased (when calcium is 1.4 *μ*M) or decreased in pump current (when calcium is 0.15 *μ*M) depending on the intracellular Ca^2+^ concentrations. In our model the resting calcium concentration was 0.12 *μ*M and the peak calcium concentration was 1.1 *μ*M. Similar to the simulation work of Heijman et al. \[[@B26]\], by simply increasing the pump current from 17% to 33%, no significant change of *I* ~NaK~ in triggering EADs (results not shown here) has been observed. However, when the continuous experimental data from human ventricular cells is available, the regulation of ISO on *I* ~NaK~ could be incorporated into the model to reconfirm this nonsignificant effect. Fifthly, it has been reported that local regulation of cAMP and substrate phosphorylation play important roles in *β*-adrenergic receptor signaling \[[@B26], [@B37]--[@B39]\], so it could be useful to incorporate local control mechanism in a future study. Lastly, there are four CaMKII isoforms (*α*, *β*, *γ*, *δ*) with different distributions, kinetics, and roles in physiological and pathological adjustments. Until now, these differences have not been fully understood. Developing a model with detailed CaMKII isoforms information could be useful when experiment data are available.

In conclusion, our simulation results computationally demonstrated a better understanding of the combinational effect of CaMKII and ISO stimulus on the occurrence of EADs in human ventricular myocyte, which may provide useful tool to research therapeutic methods for the treatment of arrhythmia.
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![(a) No EAD was produced when CaMKII phosphorylation level was in control (CaMK~0~ = 0.05). (b) Corresponding *I* ~NaL~ when no EADs occurred in (a). (c) Alternated EADs were produced when *I* ~NaL~ phosphorylation by CaMKII was enhanced with CaMK~0~ of 0.12 and other targets\' phosphorylation levels were in control (CaMK~0~ = 0.05). (d) Corresponding *I* ~NaL~ when alternated EADs occurred in (c). Under these conditions, CL was 2000 ms and *I* ~Kr~ was blocked by 85%.](CMMM2016-4576313.001){#fig1}

![(a) EADs were induced when 1 *μ*M ISO was applied and *I* ~Kr~ was blocked by 85%. In (b), EADs disappeared when *I* ~Kr~ blockage was reduced to 77%. Cycle length was set 2000 ms and CaMKII phosphorylation level to all targets was kept control (CaMK~0~ = 0.05).](CMMM2016-4576313.002){#fig2}

![EADs occurred when *I* ~Kr~ was blocked by 85% (a) and 77% (c); corresponding *I* ~NaL~ when *I* ~Kr~ was blocked by 85% (b) and 77% (d). CL was set 2000 ms, 1 *μ*M ISO was applied and CaMK~0~ for *I* ~NaL~ was set 0.12 independently.](CMMM2016-4576313.003){#fig3}

![1 *μ*M ISO was applied and cycle length was 2000 ms. CaMK~0~ for *I* ~CaL~ was 0.12 but CaMK~0~ for other targets was 0.05. EADs occurred when *I* ~Kr~ was blocked by 85% in (a), but when *I* ~Kr~ blockage was reduced to 77%, EADs vanished in (c). (b) *I* ~CaL~ figures when EADs existed. (d) *I* ~CaL~ figures when EADs vanished.](CMMM2016-4576313.004){#fig4}

###### 

Current increment and EADs occurrence when different targets were phosphorylated by CaMKII independently.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Cycle length (ms)   *I* ~Kr~ blockage level (%)     CaMKII target (CaMK~0~ = 0.12)   Target current variation        Deactivation time (ms)   EADs
  ------------------- ------------------------------- -------------------------------- ------------------------------- ------------------------ ------------
  2000                85                              *I* ~NaL~                        Decreased by 24%\               1297 versus 761 ms       Alternated
                                                                                       (from 0.25 to 0.19 *µ*A/*µ*F)                            

  *I* ~CaL~           Increased by 4.2%\                                               No                                                       
                      (from 1.67 to 1.74 *µ*A/*µ*F)                                                                                             

  *I* ~CaK~           Increased by 6.5%\                                               No                                                       
                      (from 0.62 to 0.66 *µ*A/*µ*F)                                                                                             

  *I* ~CaNa~          Increased by 8.1%\                                               No                                                       
                      (from 0.37 to 0.40 *µ*A/*µ*F)                                                                                             

  *I* ~to~            Increased by 3.2%\                                               No                                                       
                      (from 0.95 to 0.98 *µ*A/*µ*F)                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Combined effect of CaMKII overexpression and *β*-adrenergic agonist on EADs.

  Cycle length (ms)   ISO application   CaMKII target (CaMK~0~ = 0.12)   *I* ~Kr~ blockage level (%)   EADs
  ------------------- ----------------- -------------------------------- ----------------------------- ------
  2000                None              None                             85                            None
  1 *µ*M              None              85                               Yes                           
  None                77                No                                                             
  *I* ~NaL~           85                Yes                                                            
  *I* ~NaL~           77                Yes                                                            
  *I* ~CaL~           85                Yes                                                            
  *I* ~CaL~           77                No                                                             

[^1]: Academic Editor: Xiaopeng Zhao
